Ainos Past Earnings Performance

Past criteria checks 0/6

Ainos's earnings have been declining at an average annual rate of -47.5%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 32.6% per year.

Key information

-47.5%

Earnings growth rate

-3.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate32.6%
Return on equity-89.5%
Net Margin-39,705.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt

Mar 10
We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Aug 28
Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

May 15
Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Sep 30

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Aug 24

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Aug 15

Revenue & Expenses Breakdown

How Ainos makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:AIMD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-1668
30 Jun 240-1568
31 Mar 240-1567
31 Dec 230-1467
30 Sep 231-1037
30 Jun 233-1597
31 Mar 233-1497
31 Dec 224-1497
30 Sep 223-1386
30 Jun 221-725
31 Mar 221-523
31 Dec 211-422
30 Sep 211-331
30 Jun 210-220
31 Mar 210-220
31 Dec 200-110
30 Sep 200-110
30 Jun 200-110
31 Mar 200-220
31 Dec 190-220
30 Sep 190-220
30 Jun 190-220
31 Mar 190-220
31 Dec 180-110
30 Sep 180-110
30 Jun 180-110
31 Mar 180-110
31 Dec 170-110
30 Sep 170-110
30 Jun 170-110
31 Mar 170-110
31 Dec 160-110
30 Sep 160-110
30 Jun 160-110
31 Mar 160-110
31 Dec 150-110
30 Sep 150300
30 Jun 150300
31 Mar 150300
31 Dec 140300
30 Sep 140-110
30 Jun 140-110
31 Mar 140-100

Quality Earnings: AIMD is currently unprofitable.

Growing Profit Margin: AIMD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AIMD is unprofitable, and losses have increased over the past 5 years at a rate of 47.5% per year.

Accelerating Growth: Unable to compare AIMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AIMD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: AIMD has a negative Return on Equity (-89.52%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:41
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ainos, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution